Nipro Corp. (TYO:8086) and NeuroMetrix Inc. (NSDQ:NURO) announced a collaboration to market NeuroMetrix’s NC-stat diagnostic nerve testing device. The NC-stat test is a quantitative point-of-care test that evaluates systemic neuropathies like diabetic peripheral neuropathy, a common disease affecting more than half of diabetics which may lead to foot ulcers and limb amputation. This may be […]
NeuroMetrix gave back $300,000 as part of a state tax incentive program. The incentive was based on the medical device company hiring 10 new people, which did not happen.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Type 2 diabetes management is the focus and neurodiagnostics is out for NeuroMetrix. The Massachusetts medical device company said it will no longer support its nerve conduction device, laid off 27 percent of its workforce and eliminated its U.S. direct salesforce. Its next device will detect diabetic neuropathy.